JoseFranciscoLeisMDPhD

Hematologic Oncology

Physician

Dr. Leis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Jose Leis is an oncologist in Scottsdale, AZ and is affiliated with Mayo Clinic Hospital. He received his medical degree from University of Arizona College of Medicine - Tucson and has been in practice 31 years. He specializes in hematologic oncology and is experienced in acute and chronic leukemias, lymphoma, myelodysplasia, myelofibrosis, and bone marrow transplantation.

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1989 - 1993
University of California (San Diego) Medical CenterResidency, Internal Medicine, 1986 - 1989
University of Arizona College of MedicineClass of 1986

Press Ganey Top Provider Recognition Award Office of Mayo Clinic Experience, Mayo Clinic Arizona, 2020
Top Doctors:Arizona State Castle Connolly, 2013-2020
Top Faculty Award Mayo School of Continuous Professional Development, 2011-2012
Champion of Advocacy Award American Society of Hematology, 2005
Super Doctor SuperDoctors.com
Join now to see all

PubMed

Journal Articles

Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical Centre
Sameer A Parikh, Tait D Shanafelt, Paul J Hampel, Jose F Leis, Neil E Kay, Wei Ding, Timothy G Call, Deborah Bowen, Eli Muchtar, British Journal of Haematology

Abstracts/Posters

Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphoc...
Jose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (C...
Jose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
Jose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression
Jose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis
Jose F. Leis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Management of Steroid Resistant Acute and Chronic GVHD: Are We Making Progress?
CIBMTR and ASBMT BMT Tandem Meeting, Salt Lake City, UT - 2/2018
CLL: What To Do After BTK Inhibitor Therapy Fails
Great Debates & Updates in Hematologic Malignancies, New York, NY - 4/2018
How I Treat Newly Diagnosed, Relapsed, and Transformed CLL Patients
American Society of Hematology (ASH) Meeting on Hematologic Malignancies, Chicago, IL - 9/2019
Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
25th Annual North American Educational Forum on Lymphoma, Lymphoma Research Foundation - 10/25/2020
Third-line therapy and Stem Cell Transplantation for Chronic Lymphocytic Leukemia
Global Virtual Patient and Caregiver Educational Forum, CLL Society - 10/12/2020
Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all